Maximus is built around enclomiphene — a protocol that raises testosterone by stimulating your own production rather than replacing it. That mechanism preserves fertility, which conventional testosterone therapy does not.
The worth-it question therefore has an unusually clean answer. If fertility preservation is a requirement, this specialization is the product built for it. If it is not, the premium over a conventional TRT platform is buying a feature you do not need.
The cost math
One structural note before the numbers: the medication is inside the monthly fee here and the labs are outside it. That is the reverse of nearly every competitor, and it is the single most common source of budgeting error on this platform.
| Component | Cost |
|---|---|
| Maximus membership (medication included in most protocols) | $150–$300/mo |
| Initial assessment | $200–$400 one time |
| Follow-up labs | $100–$300 per panel, 3 typical in year one |
| Realistic year one all-in | $2,100–$4,500 |
| Conventional TRT platform (Hone Health) | $45–$220/mo |
| Generic testosterone cypionate at a retail pharmacy with insurance | $20–$60/mo |
| Enclomiphene at a compounding pharmacy, prescribed elsewhere | Varies; rarely insurance-covered |
| Broad physician-led program (Lifeforce or Opt Health) | $1,900–$3,000/yr plus medication |
A $150 month here and a $150 month at a platform that bills medication separately are not the same purchase. Add $300–$900 of first-year lab work to the Maximus column before comparing it against anything, and add the medication line to every other column.
The other line worth sitting with is the fifth one. Generic testosterone cypionate at a retail pharmacy through your own insurance frequently costs $20–$60 a month. If conventional TRT would work for you, that is the cheapest medication in this entire category — and enclomiphene, being off-label for this use, has no equivalent. You are paying a real premium for the fertility-preserving mechanism, and it is worth knowing exactly what that premium is.
When Maximus is worth it
- Fertility preservation matters. This is the scenario the platform exists for. Exogenous testosterone suppresses natural production and can impair fertility, sometimes for an extended period after stopping. If you may want children, this is a clinical requirement rather than a preference.
- You want the reversible option first. Stopping enclomiphene typically returns you to baseline. Stopping exogenous testosterone can leave testicular function temporarily suppressed and requires a managed restart protocol. Trying the reversible route before the committed one is a defensible sequence.
- Your own production capacity is intact. Enclomiphene works by stimulating a functioning axis. For secondary hypogonadism — where the signal is low but the testes still respond — it addresses the actual mechanism rather than working around it, which conventional therapy does not.
- You want medication cost inside a predictable fee. For enclomiphene patients the drug is in the monthly price. That removes the largest variable line item that every other prescribing platform leaves open.
When Maximus is not worth it
- You want conventional TRT and are done having children. Hone Health at $45–$220 a month covers that scope at a lower entry price, with an at-home finger-prick test.
- You want deep lab access and ancillary medications. Marek Health carries a broader a la carte menu, ancillary availability, and an 8–12 week titration cadence for complex protocols.
- You want scope beyond hormones. Lifeforce at ~$1,900/yr and Opt Health at ~$3,000/yr both extend into metabolic, thyroid, and cardiovascular work rather than treating testosterone in isolation.
- You have primary hypogonadism. If the testes themselves are not responding, stimulating the signal will not produce testosterone. Enclomiphene is the wrong mechanism for that picture, and no amount of protocol adjustment fixes it.
What would change the answer
- Completing your family. The single largest driver of this decision. Once fertility preservation stops being a requirement, the premium over conventional TRT stops buying anything and a cheaper platform covers the same outcome.
- An LH and FSH result. These markers indicate whether the signal or the gonads are the problem. Low LH with low testosterone points toward a secondary picture where enclomiphene can work. High LH with low testosterone points the other way, and changes the recommended protocol entirely.
- An inadequate response after a full trial. If testosterone has not moved meaningfully after a proper course, the mechanism is not doing its job for you. That is the point to reconsider conventional therapy rather than to escalate the dose.
- A second flagged marker. Off-range thyroid, fasting insulin, or ApoB alongside low testosterone means you are treating a pattern, and a hormone-focused platform will not see the rest of it.
What members most often regret
Assuming labs were included. Because the medication is bundled, members reasonably infer the fee is all-in. It is not — labs are separate at $100–$300 a panel, and dose-finding front-loads three of them into the first year. That is $300–$900 nobody planned for.
Starting without confirming the mechanism fits. Enclomiphene depends on a functioning axis. Members who started without an LH and FSH picture, and whose testes were the actual problem, spent months and several hundred dollars establishing that the protocol was never going to work for them.
Expecting the same response profile as testosterone therapy. Enclomiphene raises your own production, which means a slower onset and a different subjective experience than a direct injection. Members expecting the response curve of exogenous TRT sometimes read a normal enclomiphene response as a failure and quit early.
The Verdict
Yes for men who want higher testosterone while preserving fertility, or who want a reversible option before committing to exogenous therapy. No for conventional TRT — that is available at a lower entry price elsewhere, and with more lab depth at platforms built for complex protocols. No for optimization beyond hormones, where broader programs cover metabolic, thyroid, and cardiovascular work centrally.
The specialization here is genuine and the pricing reflects it fairly. The decision is not really about the platform — it is about whether the mechanism matches your clinical picture and your plans. Men who want fertility preserved, and whose LH and FSH indicate a secondary picture, are buying something they cannot get cheaply anywhere else. Men who are done having children and have a functioning conventional option are paying a premium for a feature that will never be used.
Frequently Asked Questions
Is Maximus worth it for TRT?
Yes if you specifically want an enclomiphene protocol, which raises testosterone while preserving fertility. No if you want conventional exogenous testosterone — that is available more cheaply elsewhere, and with more lab depth at platforms built around complex protocols.
Is enclomiphene as effective as traditional TRT?
For raising testosterone in men whose testes still function, yes — the mechanism differs but the outcome is real. Traditional TRT supplies testosterone directly. Enclomiphene stimulates the hypothalamic-pituitary-gonadal axis to produce more of your own. Both raise testosterone; only enclomiphene preserves fertility, and only enclomiphene depends on your own production capacity still being intact.
How much does Maximus cost?
Programs run $150–$300+ a month with medication bundled into the fee for most enclomiphene patients. Labs are billed separately at $100–$300 per panel. Year one all-in typically lands at $2,100–$4,500 once three panels are included.
Is Maximus legitimate?
Yes. It operates within standard telehealth prescribing rules, with clinician review and partner pharmacy dispensing. The differentiator is the enclomiphene specialization rather than a novel operating model. Note that enclomiphene is prescribed off-label for this use, which is common and legal but worth understanding.
What do members most often regret?
Assuming labs were included because the medication was. The bundling here is the reverse of most competitors, and members who did not budget $300–$900 for first-year lab work were caught out. The second is starting enclomiphene without confirming that natural production capacity was intact — the protocol depends on it.
Can I get enclomiphene cheaper elsewhere?
Rarely, and this is unusual for the category. Because it is prescribed off-label for this use, enclomiphene is seldom insurance-covered even at a retail pharmacy — so the "route the prescription elsewhere" lever that saves money on generic testosterone does not really exist here. The bundled price is close to the only price.